Dudediligence.

Monopar Therapeutics Inc

MNPRNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

6.71M

on 2026-06-30, from 3.50M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-5 reverse split; each bar's tip shows the count as filed.

a raise that quarter, at its price

2M4M6M1:5 splitMar2024JunSepDecMar2025JunSep$67.67DecMar2026Jun

Newest

$300.0M

S-3 of 2025-08-29. 1 prospectus supplement filed under it since. S-3 ↗

8 of its filings are not read yet.

Warrants

The 10-Q filed 2026-08-12 is not read yet.

Cash

34.6 quarters

$105.4M on 2026-06-30 ÷ $3.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-09-23Public offering incl. 0.96M pre-funded1,994,975$67.67$135.0M424B5 ↗